Updates to the Updates in Pharmacotherapy

Learning Objectives

**Psychiatry**

Jacintha S. Cauffield, Pharm.D., BCPS

*Associate Professor of Pharmacy Practice, The Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, Florida*

1. Discuss the updates presented Diagnostic and Statistical Manual, 5th edition and how they vary from the previous edition (DSM-IV-TR).
2. Distinguish the differences in newly approved medications from previous treatment modalities in the treatment of depression.
3. Distinguish between patients with bipolar type I and bipolar type II.
5. Assess the appropriateness of the use of an antidepressant to treat an individual patient with bipolar disorder in light of recent findings.

**Oncology**

Sarah L. Scarpace, Pharm.D., BCOP

*Associate Professor and Assistant Dean for Pharmacy Professional Affairs, Albany College of Pharmacy and Health Sciences; Clinical Pharmacy Specialist, Stratton Veterans’ Affairs Medical Center, Albany, New York*

1. Describe updates in the screening recommendations for patients with lung cancer.
2. Describe the pharmacology, efficacy, safety, and key counseling and monitoring parameters of these newly FDA-approved drug therapies:
   a. Afatinib (non-small cell lung cancer)
   b. Pertuzumab (breast cancer)
   c. Dabrafenib (melanoma)
   d. Trametinib (melanoma)
   e. Ibrutinib (mantle cell lymphoma)
   f. Lenalidomide (mantle cell lymphoma)
   g. Obinutuzumab (chronic lymphocytic leukemia)
   h. Pomalidomide (multiple myeloma)
   i. Vandetanib (medullary thyroid cancer)
   j. Regorafenib (gastrointestinal stromal tumor)
   k. Denosumab (giant cell tumor of the bone)
   l. Nab-paclitaxel (pancreatic cancer)
3. Describe the role of afatinib and pertuzumab in the management of patients with NSCLC and breast cancer, respectively.
4. Describe the rationale and implications of the FDA’s decision to suspend marketing of ponatinib.
Neurology

Jacquelyn L. Bainbridge, Pharm.D., FCCP
Professor, Department of Clinical Pharmacy and Department of Neurology, University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy & Pharmaceutical Sciences, Aurora, Colorado

1. Describe the black box warning added to the package insert for Ezogabine.
2. List the recent antiepileptic drugs FDA approved for epilepsy.

Cardiology I

Shannon W. Finks, Pharm.D., FCCP, BCPS
Associate Professor, University of Tennessee College of Pharmacy, Clinical Pharmacy Specialist, Cardiology, Veterans Affairs Medical Center, Memphis, Tennessee

1. Develop an evidence-based pharmacological regimen for patients with hypertension according to new practice guidelines and clinical trial evidence
2. Evaluate areas of disagreement among recent hypertension guideline publications
3. Formulate patient-specific pharmacologic therapy goals for patients with heart failure, with an emphasis on new guideline changes

Cardiology II

Karen J. McConnell, Pharm.D., FCCP, BCPS (AQ Cardiology)
Clinical Pharmacy Specialist in Cardiology – Kaiser Permanente of Colorado; Clinical Associate Professor – University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; Adjunct Professor of Pharmacy Practice – Regis University School of Pharmacy, Denver, Colorado

1. Recommend lifestyle management to reduce cardiovascular risk based on the 2013 ACC/AHA guidelines
2. Calculate 10 year and lifetime risk of atherosclerotic cardiovascular disease (ASCVD) using the pooled cohort equation from the 2013 ACC/AHA guidelines
3. Create an evidence based medication regimen to treat cholesterol for primary and secondary prevention based on the 2013 ACC/AHA cholesterol guidelines
4. Develop a treatment strategy for dyslipidemia for patient with chronic kidney disease based on the 2013 Kidney Disease Improving Global Outcomes (KDIGO) guidelines

Gastrointestinal Disorders

Brian A. Hemstreet, Pharm.D., FCCP, BCPS
Assistant Dean for Student Affairs, Associate Professor, Regis University School of Pharmacy, Rueckert-Hartman College for Health Professions, Denver, Colorado

1. Evaluate new guideline recommendations for the treatment of Crohn’s Disease.
2. Assess the recommended processes for pre and post-exposure prophylaxis of healthcare personnel against hepatitis B virus.